{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:18:51Z","timestamp":1791379131705,"version":"4.3.2"},"reference-count":11,"publisher":"MedWorks Media","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>NTX is FDA-approved for opiate and alcohol use disorders as anti-craving agent. It has been used successfully off-label in other psychiatric indications. Here, we shed some light on these while examining the extant evidence.<\/jats:p>","DOI":"10.64719\/pb.4496","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"97-99","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic Potential of Naltrexone in the Niche of Psychopharmacology"],"prefix":"10.64719","volume":"54","author":[{"given":"Ahmed","family":"Naguy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bibi","family":"Alamiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Naguy A, Badr BHM. Buprobion-Myth-Busting. CNS Spetr. 2021;27(5):545\u2013546.","DOI":"10.1017\/S1092852921000365"},{"key":"ref2","unstructured":"Naguy A. Viewpoint: Borderline Personality Disorder-Light At the End of the Tunnel. Isr J Psychiatry Relat Sci. 2020;57(1):41\u201343."},{"key":"ref3","unstructured":"Moghaddas A, Dianatkhah M, Ghaffari S et al. The Potential Role of Naltrexone in Borderline Personality Disorder. Iran J Psychiatry. 2017;12(2):142\u2013146."},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Elchaar GM, Maisch NM, Augusto LMG et al. Efficacy and Safety of Naltrexone Use in Pediatric Patients with Autistic Disorder. Ann Pharmacother. 2006;40(6):1086\u20131095.","DOI":"10.1345\/aph.1G499"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Bartley CA, Bloch MH. Meta-Analysis: Pharmacological Treatment of Pathological Gambling. Expert Rev Neurother. 2013;13:887\u2013894.","DOI":"10.1586\/14737175.2013.814938"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Stancil SL, Adelman W, Dietz A et al. Naltrexone Reduces Binge Eating and Purging in Adolescents in an Eating Disorder Program. J Child Adolesc Psychopharmacol. 2019;29(9):721\u2013724.","DOI":"10.1089\/cap.2019.0056"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Savard J, Oberg KG, Chatzittofis A et al. Naltrexone in Compulsive Sexual Behaviour Disorder: A Feasibility Study of Twenty Men. J Sex Med. 2020;17(8):1544\u20131552.","DOI":"10.1016\/j.jsxm.2020.04.318"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Ryback RS. Naltrexone in the Treatment of Adolescent Sexual Offenders. J Clin Psychiatry. 2004;65(7):982\u2013986.","DOI":"10.4088\/JCP.v65n0715"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Firoz K, Sankar VN, Rajmohan V et al. Treatment of Fetishism with Naltrexone: A Case Report. Asian J Psychiatr. 2014;8:67\u201368.","DOI":"10.1016\/j.ajp.2013.11.006"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Naguy A, Pridmore S, Moodliar-Rensburg S et al. A Difficult Case of Satyriasis in an Adolescent Responding Ultimately to a Combination of Paliperidone Palmitate and Naltrexone. CNS Spectr. 2022;27(4):386\u2013387.","DOI":"10.1017\/S1092852920002230"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Escamilla I, Juan N, Penalva C et al. Treatment of Dissociative Symptoms with Opioid Antagonists: A Systematic Review. Eur J Psychotraumatol. 2023;14(2):2265184.","DOI":"10.1080\/20008066.2023.2265184"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:32:43Z","timestamp":1791315163000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/therapeutic-potential-of-naltrexone-in-the-niche-of-psychopharmacology\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":11,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4496","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}